Nothing Special   »   [go: up one dir, main page]

EA032938B1 - Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения - Google Patents

Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения

Info

Publication number
EA032938B1
EA032938B1 EA201792597A EA201792597A EA032938B1 EA 032938 B1 EA032938 B1 EA 032938B1 EA 201792597 A EA201792597 A EA 201792597A EA 201792597 A EA201792597 A EA 201792597A EA 032938 B1 EA032938 B1 EA 032938B1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
compound
composition based
preparing same
glutarimide derivative
Prior art date
Application number
EA201792597A
Other languages
English (en)
Other versions
EA201792597A3 (ru
EA201792597A2 (ru
Inventor
Владимир Евгеньевич НЕБОЛЬСИН
Татьяна Александровна КРОМОВА
Original Assignee
Общество С Ограниченной Ответственностью "Атд Терапевтикс"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2013116826A external-priority patent/RU2562773C3/ru
Application filed by Общество С Ограниченной Ответственностью "Атд Терапевтикс" filed Critical Общество С Ограниченной Ответственностью "Атд Терапевтикс"
Publication of EA201792597A2 publication Critical patent/EA201792597A2/ru
Publication of EA201792597A3 publication Critical patent/EA201792597A3/ru
Publication of EA032938B1 publication Critical patent/EA032938B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Изобретение относится к соединению формулыили его фармацевтически приемлемой соли, его применению в качестве средства для лечения заболеваний дыхательных путей, способу лечения заболеваний дыхательных путей, включающему введение пациенту указанного соединения, фармацевтической композиции, содержащей указанное соединение, и способу получения указанного соединения путем нагревания моноамида дикарбоновой кислоты формулыгде m, R, R, R, R, R, R, Rи Rопределены в формуле изобретения с водоотнимающим агентом в органическом растворителе.
EA201792597A 2013-04-12 2014-04-10 Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения EA032938B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2013116826A RU2562773C3 (ru) 2013-04-12 Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения

Publications (3)

Publication Number Publication Date
EA201792597A2 EA201792597A2 (ru) 2018-04-30
EA201792597A3 EA201792597A3 (ru) 2018-09-28
EA032938B1 true EA032938B1 (ru) 2019-08-30

Family

ID=51689819

Family Applications (4)

Application Number Title Priority Date Filing Date
EA201591957A EA031392B1 (ru) 2013-04-12 2014-04-10 Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
EA201792072A EA032951B1 (ru) 2013-04-12 2014-04-10 Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения
EA201792597A EA032938B1 (ru) 2013-04-12 2014-04-10 Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения
EA201792071A EA033054B1 (ru) 2013-04-12 2014-04-10 Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EA201591957A EA031392B1 (ru) 2013-04-12 2014-04-10 Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
EA201792072A EA032951B1 (ru) 2013-04-12 2014-04-10 Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201792071A EA033054B1 (ru) 2013-04-12 2014-04-10 Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения

Country Status (15)

Country Link
US (8) US9815814B2 (ru)
EP (3) EP3725785B1 (ru)
JP (4) JP6529958B2 (ru)
KR (3) KR102296182B1 (ru)
CN (4) CN110128406B (ru)
AU (5) AU2014251442A1 (ru)
BR (3) BR122020010204B1 (ru)
CA (1) CA2909057C (ru)
EA (4) EA031392B1 (ru)
IL (4) IL266301B2 (ru)
MX (4) MX2020005735A (ru)
SG (4) SG11201508394UA (ru)
UA (1) UA121299C2 (ru)
WO (1) WO2014168522A1 (ru)
ZA (3) ZA201508278B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201508394UA (en) 2013-04-12 2015-11-27 Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmentpr Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
RU2552929C1 (ru) 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
RU2628800C2 (ru) * 2014-03-12 2017-08-22 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами
CN106539792B (zh) * 2016-11-07 2017-08-25 王晓旭 一种治疗高血脂症的药物
GEP20227402B (en) * 2017-09-07 2022-08-10 Valenta Intellekt Ltd Use of glutarimide derivative to treat diseases related to aberrant activity of cytokines
CA3118438A1 (en) * 2018-11-01 2020-05-07 Ahammune Biosciences Private Limited Novel imidazole compounds, process for the synthesis and uses thereof
RU2712281C1 (ru) * 2018-11-23 2020-01-28 Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
WO2021262040A1 (ru) * 2020-06-26 2021-12-30 Общество С Ограниченной Ответственностью "Валента-Интеллект" Применение производного глутаримида для терапии заболеваний, ассоциированных с аберрантной активностью интерлейкина-6
WO2023121519A1 (ru) * 2021-12-23 2023-06-29 Общество С Ограниченной Ответственностью "Валента-Интеллект" Применение 1-[2-(1-метилимидазол-4-ил)-этил]пергидроазин-2,6-диона для лечения covid-19
WO2023177329A1 (ru) * 2022-03-18 2023-09-21 Общество С Ограниченной Ответственностью "Валента-Интеллект" Применение 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона для лечения кашля, вызванного вирусными инфекциями
WO2023191666A1 (ru) * 2022-03-29 2023-10-05 Общество С Ограниченной Ответственностью "Валента-Интеллект" Кристаллическая форма 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона и ее применение
WO2023249516A1 (ru) * 2022-06-24 2023-12-28 Общество С Ограниченной Ответственностью "Валента-Интеллект" Новая кристаллическая форма 1-[2-(1-метилимидазол-4-ил)этил]пергидроазин-2,6-диона и ее фармацевтическое применение

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1836365A3 (ru) * 1991-01-24 1993-08-23 Физиko-Xиmичeckий Иhctиtуt Иm.A.B.Бoгatckoгo;Hии@ Фapmakoлoгии Poccийckoй Amh Способ получения ν-0-пиперазинил)бутилглутаримидов
WO2001005765A1 (en) * 1999-07-15 2001-01-25 Recordati Industria Chimica E Farmaceutica Spa Cyclic amides and imides having selective antagonist activity at alpha-1d adrenergic receptor
RU2278857C2 (ru) * 2000-01-21 2006-06-27 Грюненталь Гмбх Замещенные глутаримиды, способы получения и лекарственное средство на их основе

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3081308A (en) * 1959-12-29 1963-03-12 Searle & Co 5-carbocyclic-3-imidomethyloxazolidines and process
US3171839A (en) * 1961-05-18 1965-03-02 Searle & Co 4-alkyl-1-(cyclic imidoalkyl) piperidines
GB1033251A (en) * 1961-09-07 1966-06-22 Distillers Co Yeast Ltd Glutarimide derivatives
US3963691A (en) * 1974-10-07 1976-06-15 Merck & Co., Inc. Synthetic antigens of luteinizing hormone releasing hormone
US4261990A (en) * 1979-03-09 1981-04-14 Ciba-Geigy Corporation N-alkyleneiminoalkyl-dicarboximides as antiallergics and antiasthmatics
JPS606686A (ja) 1983-06-27 1985-01-14 Kissei Pharmaceut Co Ltd チオフエン誘導体及びその製造方法
JPS6066686A (ja) 1983-09-19 1985-04-16 Toshiba Corp ライン駆動電動機の速度制御装置
SE8600261D0 (sv) * 1986-01-21 1986-01-21 Lundblad Leif Indolokinoxaliner med substituenter i 6-position som innehaller cykliska grupper
FR2737725B1 (fr) 1995-08-08 1997-10-31 Valentonine Nouveaux derives acyles de la melatonine et d'analogues melatoninergiques, leur procede de preparation et leur utilisation en tant que medicament
RU2141483C1 (ru) 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция
WO1999012910A1 (fr) * 1997-09-11 1999-03-18 Nissan Chemical Industries, Ltd. Composes a base de pyrazole et agent de lutte contre les maladies vegetales
US6413428B1 (en) 1999-09-16 2002-07-02 Berger Instruments, Inc. Apparatus and method for preparative supercritical fluid chromatography
US7030150B2 (en) * 2001-05-11 2006-04-18 Trimeris, Inc. Benzimidazole compounds and antiviral uses thereof
WO2004022536A1 (en) * 2002-09-04 2004-03-18 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
MXPA05013224A (es) 2003-06-12 2006-03-09 Novo Nordisk As Piridinilcarbamatos como inhibidores de lipasa sensible a hormonas.
CN1260218C (zh) * 2003-11-06 2006-06-21 天津药物研究院 一类pdf酶抑制剂－异羟肟酸系列化合物及其合成方法与用途
WO2006040646A1 (en) * 2004-10-14 2006-04-20 Pfizer, Inc. Benzimidazole or indole amides as inhibitors of pin1
AU2006219231B2 (en) * 2005-02-28 2010-01-14 Japan Tobacco Inc. Novel aminopyridine compound with Syk inhibitory activity
EP1741709A1 (en) * 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
WO2007007054A1 (en) * 2005-07-08 2007-01-18 Cancer Research Technology Limited Phthalamides, succinimides and related compounds and their use as pharmaceuticals
US20120157387A1 (en) * 2006-11-28 2012-06-21 Apotex Technologies Inc. Orally bioavailable d-gamma-glutamyl-d-tryptophan
WO2010033339A1 (en) * 2008-09-16 2010-03-25 The Trustees Of The University Of Pennsylvania Inhibition of influenza m2 proton channel
MX2012011938A (es) * 2010-04-15 2013-01-28 Biota Scient Management Compuesto para tratamiento de condicion o enfermedad respiratoria.
TW201217312A (en) * 2010-09-22 2012-05-01 Gruenenthal Gmbh Substituted benzamide compounds
US20120157382A1 (en) * 2010-12-21 2012-06-21 Siegfried Krimmer Pharmaceutical glp-1 compositions having an improved release profile
RU2665688C2 (ru) * 2013-04-12 2018-09-04 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Производные бисамидов дикарбоновых кислот, их применение, фармацевтическая композиция на их основе, способы их получения
SG11201508394UA (en) 2013-04-12 2015-11-27 Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmentpr Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
RU2552929C1 (ru) * 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1836365A3 (ru) * 1991-01-24 1993-08-23 Физиko-Xиmичeckий Иhctиtуt Иm.A.B.Бoгatckoгo;Hии@ Фapmakoлoгии Poccийckoй Amh Способ получения ν-0-пиперазинил)бутилглутаримидов
WO2001005765A1 (en) * 1999-07-15 2001-01-25 Recordati Industria Chimica E Farmaceutica Spa Cyclic amides and imides having selective antagonist activity at alpha-1d adrenergic receptor
RU2278857C2 (ru) * 2000-01-21 2006-06-27 Грюненталь Гмбх Замещенные глутаримиды, способы получения и лекарственное средство на их основе

Also Published As

Publication number Publication date
AU2018236805C1 (en) 2020-11-05
IL266301B2 (en) 2023-03-01
EP3722290A1 (en) 2020-10-14
EA032951B1 (ru) 2019-08-30
WO2014168522A9 (ru) 2014-12-04
CA2909057A1 (en) 2014-10-16
AU2014251442A1 (en) 2015-12-03
RU2562773C2 (ru) 2015-09-10
SG10201802648SA (en) 2018-05-30
BR122020010204B1 (pt) 2022-03-03
CN110172055B (zh) 2021-10-29
EA201792072A2 (ru) 2018-04-30
AU2020203630A1 (en) 2020-06-25
EP2985282A4 (en) 2017-02-22
MX2020005736A (es) 2021-06-14
WO2014168522A4 (ru) 2015-01-22
US20180016256A1 (en) 2018-01-18
BR122020010210B1 (pt) 2022-09-20
IL266302B (en) 2021-09-30
IL266301B (en) 2022-11-01
US20180016253A1 (en) 2018-01-18
BR112015025804A2 (pt) 2017-07-25
JP2016516766A (ja) 2016-06-09
US20190084961A1 (en) 2019-03-21
EA201792071A3 (ru) 2018-09-28
KR102296182B1 (ko) 2021-09-02
JP6627039B2 (ja) 2020-01-08
US10377739B2 (en) 2019-08-13
ZA201603109B (en) 2017-08-30
US10155746B2 (en) 2018-12-18
KR102254315B1 (ko) 2021-05-25
SG10201802650WA (en) 2018-05-30
AU2018236805B2 (en) 2020-04-09
CN110172055A (zh) 2019-08-27
CN110229140B (zh) 2022-06-10
AU2020203968A1 (en) 2020-07-02
EA201792071A2 (ru) 2018-04-30
KR20200069380A (ko) 2020-06-16
KR20200069381A (ko) 2020-06-16
RU2013116826A (ru) 2014-10-20
JP6529958B2 (ja) 2019-06-12
US10196377B2 (en) 2019-02-05
US10155745B2 (en) 2018-12-18
EP3722290B1 (en) 2023-06-21
MX2020005738A (es) 2021-08-13
US20180016255A1 (en) 2018-01-18
EA201792597A3 (ru) 2018-09-28
EA201792072A3 (ru) 2018-09-28
JP6843103B2 (ja) 2021-03-17
AU2020203632B2 (en) 2021-04-22
AU2018236805A1 (en) 2018-10-18
JP2019034964A (ja) 2019-03-07
JP6620324B2 (ja) 2019-12-18
MX2020005735A (es) 2021-06-21
ZA201508278B (en) 2017-11-29
UA121299C2 (uk) 2020-05-12
SG10201802647QA (en) 2018-05-30
AU2020203968B2 (en) 2021-04-22
BR112015025804B1 (pt) 2022-01-04
IL266300A (en) 2019-06-30
MX2015014336A (es) 2016-06-07
IL266302A (en) 2019-06-30
EA031392B1 (ru) 2018-12-28
US9815814B2 (en) 2017-11-14
IL266301A (en) 2019-06-30
KR20160021092A (ko) 2016-02-24
EP3725785A1 (en) 2020-10-21
SG11201508394UA (en) 2015-11-27
EP3725785B1 (en) 2024-04-10
EP2985282A1 (en) 2016-02-17
US20160046598A1 (en) 2016-02-18
KR102255929B1 (ko) 2021-05-26
AU2020203632A1 (en) 2020-06-25
CN110229140A (zh) 2019-09-13
CN110128406B (zh) 2021-08-27
WO2014168522A1 (ru) 2014-10-16
AU2020203630B2 (en) 2021-04-22
JP2019034965A (ja) 2019-03-07
ZA201603108B (en) 2017-08-30
US10155743B2 (en) 2018-12-18
CN106061962B (zh) 2019-09-06
EA033054B1 (ru) 2019-08-30
US10155744B2 (en) 2018-12-18
JP2019034966A (ja) 2019-03-07
US20180016254A1 (en) 2018-01-18
CN110128406A (zh) 2019-08-16
EA201792597A2 (ru) 2018-04-30
EP3725785C0 (en) 2024-04-10
EA201591957A1 (ru) 2016-02-29
US20180022728A1 (en) 2018-01-25
US10155747B2 (en) 2018-12-18
IL266300B (en) 2021-10-31
CA2909057C (en) 2022-03-22
CN106061962A (zh) 2016-10-26
US20180016257A1 (en) 2018-01-18
IL241998B (en) 2019-06-30

Similar Documents

Publication Publication Date Title
EA032938B1 (ru) Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения
MD20140063A2 (ru) Производные бензотиазол-6-ил уксусной кислоты и их применение для лечения инфекции ВИЧ
PH12014502041A1 (en) Heterocyclyl compounds as mek inhibitors
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
WO2013123215A3 (en) Antiviral drugs for treatment of arenavirus infection
MX2015004362A (es) Derivados de ketamina.
NZ702835A (en) 3-o-heteroaryl-ingenol
MX366309B (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
JP2017517574A5 (ru)
WO2015139638A8 (en) Salts of hexahydropentaleno derivatives, preparation method and use in medicine thereof
WO2014060942A3 (en) Compositions and methods of for the treatment of multiple sclerosis and neurodegenerative diseases
NZ724063A (en) Pyrazine derivatives having pharmaceutical activity
WO2014170820A3 (en) A pharmaceutical combination for treating tuberculosis
RU2014104644A (ru) Способ повышения эффективности лечения коров, больных острым гнойно-катаральным эндометритом

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM